Erik Lium, PhD, Promoted to Executive Vice President of Mount Sinai Innovation Partners
The Mount Sinai Health System has announced Erik Lium, PhD, has been promoted to Executive Vice President of Mount Sinai Innovation Partners (MSIP). His new, expanded role will include broad responsibilities for innovation, commercialization, and entrepreneurship across the Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai.
“Mount Sinai is proud to announce the promotion of Dr. Lium, to further develop innovation across the health system which is a critical part of our success and institutional agenda,” said Kenneth L. Davis, MD, President and CEO of the Mount Sinai Health System. “MSIP serves a vital role in medicine to facilitate discoveries, and I have full confidence in Dr. Lium to lead the development of major breakthroughs in healthcare.”
More specifically Dr. Lium will be in charge of advancing Mount Sinai’s research, educational, and public service missions through strategic partnerships with industry. He will also oversee the management, licensing, and commercialization of Mount Sinai technologies, and foster innovation and entrepreneurship within the Mount Sinai life sciences ecosystem. In this expanded role, Dr. Lium will help create economic development initiatives to evolve Mount Sinai’s innovation ecosystem, and oversee the creation and growth of the i3 Asset Accelerator, which advances the development of discoveries for licensing and commercial development. Additionally, Dr. Lium will further represent the institution’s interests related to new companies launched by Mount Sinai Innovation Partners, and will advise Mount Sinai Ventures, which invests in health care businesses focused on population health management.
“I’m pleased to build upon the strong momentum within Mount Sinai’s life science ecosystem. I look forward to directing our community’s passion and expertise in research, translation and commercialization to advance healthcare breakthroughs to the global patient population more quickly,” said Dr. Lium.
Under Dr. Lium’s leadership and through Mount Sinai’s expansive network of industry partnerships, and vast array of innovators in the fields of drugs, devices, diagnostics, and digital health, it has become a globally recognized leader in technology commercialization. Most recently, MSIP launched RenalytixAI, an artificial intelligence company aimed at risk-stratifying patients with advanced kidney disease, treating early-stage patients, and improving detection for at-risk populations.
Dr. Lium joined Mount Sinai as Vice President of MSIP in 2014 and was named Senior Vice President in 2016. Earlier, he held positions at the University of California, San Francisco (UCSF), including Assistant Vice Chancellor of Innovation, Technology and Alliances; UCSF Principal Investigator for the Bay Area National Science Foundation I-Corps node; and Assistant Vice Chancellor of Research. He also served as Founder and President of LabVelocity Inc., information services company focused on accelerating research and development in the life sciences.
Dr. Lium earned his PhD in Cellular, Molecular and Biophysical Studies at Columbia University and pursued post-doctoral training at UCSF.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.